ReviewGenes2024
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies.
Abstract readReview
In one paragraph
Review in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Integrated WGCNA, Network Pharmacology, and UPLC-MS/MS Profiling for Investigating the Antitumor Effects of the Kansui Radix Dichloromethane Fraction Against Renal Cell Carcinoma with Experimental Validation.International journal of molecular sciences · 2026Article
- Von Hippel-Lindau Syndrome: An Updated Narrative Review for the First-Contact Clinician.Cureus · 2026Review
- Review
- Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies.Cancers · 2026Review
- Repressive regulatory function of seryl-tRNA synthetase on VEGFA gene expression is impaired in renal cell carcinoma.Croatian medical journal · 2026Article
- Exploratory Multi-Level Analysis of the HIF Axis in Clear-Cell Renal Cell Carcinoma and Evaluation of GN44028 as an Experimental HIF Pathway-Modulating Compound.International journal of molecular sciences · 2026Article
- PCDHGC3 silencing promotes clear cell renal cell carcinoma metastasis via mTOR/HIF2α activation, lipid metabolism rewiring, and ferroptosis evasion.Cell death & disease · 2026Article
- USP10 regulates HIF2α stability by deubiquitinating HIF2α regardless ofTranslational andrology and urology · 2026Article
- Oncometabolites and Hypoxia-Regulated Exosomes Shape HIF-Driven Macrophage Programs Across Type 2 Diabetes, Atherosclerosis, and Cancer.International journal of molecular sciences · 2026Review
- Advances in immunotherapy for renal cell carcinoma: a comprehensive review.Frontiers in immunology · 2026Review
- Metabolism of myeloid cells in brain tumors.Frontiers in immunology · 2026Review
- Late cutaneous metastasis of clear-cell renal cell carcinoma to the lower eyelid five years after radical nephrectomy: A case report.Urology case reports · 2025Article
- Upregulation ofInternational journal of molecular sciences · 2025Article
- Regulation of Erythropoietin Activity in Clear Renal Cell Carcinoma.International journal of molecular sciences · 2025Article
- Gastric metastasis of renal cell carcinoma: features, mechanisms, and insights from existing literature.Frontiers in cell and developmental biology · 2025Review
- ReducedCancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Giandomenico RovielloDepartment of Health Science, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-5504-8237
Irene De GennaroDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Ismaela VascottoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Giulia VenturiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Alberto D'AngeloDepartment of Medicine, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield S10 2JF, UK.ORCID 0000-0001-8417-9172
Costanza WinchlerDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Adriana GuarinoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Salvatore CacioppoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Mikol ModestiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Marinella Micol MelaClinical Oncology Unit, Careggi University Hospital, 50234 Florence, Italy.
Edoardo FranciniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-4270-7023
Laura DoniClinical Oncology Unit, Careggi University Hospital, 50234 Florence, Italy.
Virginia RossiClinical Oncology Unit, Careggi University Hospital, 50234 Florence, Italy.
Elisabetta GambaleClinical Oncology Unit, Careggi University Hospital, 50234 Florence, Italy.
Roberta GiorgioneDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-1674-6312
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Gabriella NesiDepartment of Health Sciences, Section of Anatomic Pathology, University of Florence, 50139 Florence, Italy.ORCID 0000-0002-2614-944X
Martina CatalanoDepartment of Health Science, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-1856-2848
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations of the von Hippel-Lindau (
Indexed as
Basic Helix-Loop-Helix ProteinsCarcinoma, Renal CellHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsEndothelial PAS Domain-Containing Protein 1HumansMolecular Targeted TherapyVon Hippel-Lindau Tumor Suppressor ProteinBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinbelzutifanHIF-2α targetingrenal cell carcinomaVHL tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.